They are waiving cost sharing for COVID-19 treatment. How large will premium increases be next year?
New point-of-care tools offer greater transparency.
Payers are finding ways for members to afford expensive specialty drug treatments.
Authorized generics have been gaining popularity with pharmaceutical manufacturers, but just how do they impact pharmacies?
Drug shortages might be decreasing, but their continued existence is urging the pharmacy industry to maintain its vigilance.
Opportunities to lower drug prices, as promised by President Trump’s American Patients First Blueprint, are picking up steam, some progressing more quickly than others.
CMS introduced indication-based formularies as a voluntary tool for plans to implement in 2020.
The real-world strategies used to manage the high cost of specialty meds.
The Trump Administration has taken a large interest in PBM drug rebates, which they say create higher drug prices. But do they?
The stakes have never been higher in reducing readmissions and hospitals are leveraging pharmacists’ expertise and putting them at the forefront of readmission reduction programs